NASDAQ:DBVT - DBV TECHNOLOGIE/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$8.36 -0.11 (-1.30 %)
(As of 03/20/2019 09:55 AM ET)
Previous Close$8.47
Today's Range$8.36 - $8.36
52-Week Range$3.60 - $25.77
Volume2 shs
Average Volume376,449 shs
Market Capitalization$496.92 million
P/E Ratio-2.50
Dividend YieldN/A
Beta1.98
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Receive DBVT News and Ratings via Email

Sign-up to receive the latest news and ratings for DBVT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:DBVT
CUSIPN/A
Phone33-1-55-42-78-78

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.45 million
Book Value$2.94 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$496.92 million
Next Earnings Date3/22/2019 (Estimated)
OptionableOptionable

DBV TECHNOLOGIE/S (NASDAQ:DBVT) Frequently Asked Questions

What is DBV TECHNOLOGIE/S's stock symbol?

DBV TECHNOLOGIE/S trades on the NASDAQ under the ticker symbol "DBVT."

How were DBV TECHNOLOGIE/S's earnings last quarter?

DBV TECHNOLOGIE/S (NASDAQ:DBVT) issued its earnings results on Thursday, March, 26th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.35. View DBV TECHNOLOGIE/S's Earnings History.

When is DBV TECHNOLOGIE/S's next earnings date?

DBV TECHNOLOGIE/S is scheduled to release their next quarterly earnings announcement on Friday, March 22nd 2019. View Earnings Estimates for DBV TECHNOLOGIE/S.

What price target have analysts set for DBVT?

9 brokers have issued twelve-month price targets for DBV TECHNOLOGIE/S's stock. Their forecasts range from $5.25 to $33.00. On average, they expect DBV TECHNOLOGIE/S's share price to reach $17.6563 in the next year. This suggests a possible upside of 111.2% from the stock's current price. View Analyst Price Targets for DBV TECHNOLOGIE/S.

What is the consensus analysts' recommendation for DBV TECHNOLOGIE/S?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DBV TECHNOLOGIE/S in the last year. There are currently 1 sell rating, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for DBV TECHNOLOGIE/S.

What are Wall Street analysts saying about DBV TECHNOLOGIE/S stock?

Here are some recent quotes from research analysts about DBV TECHNOLOGIE/S stock:
  • 1. Stifel Nicolaus analysts commented, "We are reiterating our Hold rating on DBVT shares after the company provided its 4Q18 business and financial update. We revise our model accordingly. As we indicated in our AAAAI recap/KOL dinner note, while the ICER analysis evaluating the cost effectiveness of peanut immunotherapies could pose a headwind for both DBVT and AIMT (Hold, $25.48), we do think the risk/reward for DBVT is probably more favorable at these levels if management is able to re-file its BLA on time in 3Q19, gain BLA acceptance from the FDA and its Adcom is eventually positive. With that said, we remain on the sidelines for now until management executes on its near-term regulatory initiatives and addresses its current capital overhang. We maintain our Hold rating and $10 target price." (3/6/2019)
  • 2. According to Zacks Investment Research, "DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. " (12/17/2018)

Has DBV TECHNOLOGIE/S been receiving favorable news coverage?

Media headlines about DBVT stock have been trending somewhat negative on Wednesday, according to InfoTrie. The research group identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. DBV TECHNOLOGIE/S earned a media sentiment score of -1.1 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an impact on the stock's share price in the near term.

Are investors shorting DBV TECHNOLOGIE/S?

DBV TECHNOLOGIE/S saw a increase in short interest during the month of February. As of February 15th, there was short interest totalling 2,182,143 shares, an increase of 36.3% from the January 31st total of 1,601,337 shares. Based on an average trading volume of 445,284 shares, the short-interest ratio is presently 4.9 days. Currently, 3.6% of the company's shares are sold short. View DBV TECHNOLOGIE/S's Current Options Chain.

Who are some of DBV TECHNOLOGIE/S's key competitors?

What other stocks do shareholders of DBV TECHNOLOGIE/S own?

Who are DBV TECHNOLOGIE/S's key executives?

DBV TECHNOLOGIE/S's management team includes the folowing people:
  • Dr. Pierre-Henri Benhamou, Co-Founder & Non-Exec. Chairman (Age 64)
  • Mr. David Schilansky, Deputy CEO & CFO (Age 44)
  • Dr. Laurent Martin, Chief Devel. Officer (Age 52)
  • Mr. Daniel Tassé, Chief Exec. Officer (Age 59)
  • Mr. Bertrand Dupont, Co-Founder & CTO (Age 67)

Who are DBV TECHNOLOGIE/S's major shareholders?

DBV TECHNOLOGIE/S's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (2.77%), FMR LLC (1.93%), First Midwest Bank Trust Division (1.66%), Perceptive Advisors LLC (1.39%), Jennison Associates LLC (0.90%) and BlackRock Inc. (0.51%).

Which major investors are selling DBV TECHNOLOGIE/S stock?

DBVT stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Jennison Associates LLC, FMR LLC, BlackRock Inc., Geode Capital Management LLC and Geode Capital Management LLC.

Which major investors are buying DBV TECHNOLOGIE/S stock?

DBVT stock was purchased by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, First Midwest Bank Trust Division, Premier Asset Management LLC, OLD Mission Capital LLC, Exane Asset Management and Norges Bank.

How do I buy shares of DBV TECHNOLOGIE/S?

Shares of DBVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is DBV TECHNOLOGIE/S's stock price today?

One share of DBVT stock can currently be purchased for approximately $8.36.

How big of a company is DBV TECHNOLOGIE/S?

DBV TECHNOLOGIE/S has a market capitalization of $496.92 million and generates $13.45 million in revenue each year. The company earns $-166,930,000.00 in net income (profit) each year or ($3.37) on an earnings per share basis.

What is DBV TECHNOLOGIE/S's official website?

The official website for DBV TECHNOLOGIE/S is http://www.dbv-technologies.com.

How can I contact DBV TECHNOLOGIE/S?

DBV TECHNOLOGIE/S's mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The company can be reached via phone at 33-1-55-42-78-78 or via email at [email protected]


MarketBeat Community Rating for DBV TECHNOLOGIE/S (NASDAQ DBVT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  279 (Vote Outperform)
Underperform Votes:  293 (Vote Underperform)
Total Votes:  572
MarketBeat's community ratings are surveys of what our community members think about DBV TECHNOLOGIE/S and other stocks. Vote "Outperform" if you believe DBVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DBVT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/20/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel